Neuronetics Explained

Neuronetics, Inc.
Type:	Public
Traded As:	NASDAQ: Russell 2000 Index component
Key People:	Keith J. Sullivan (President and CEO)^[1] ^[2] Stephen Furlong (CFO)Andrew Macan (General counsel) ^[3]
Num Employees:	167 ^[4]
Foundation:	2003
Location:	Malvern, PA, United States

Neuronetics is a Malvern, PA based, publicly traded company incorporated in Delaware in April 2003,^[4] that develops non-invasive treatments for psychiatric disorders that have shown resistance or lack of improvement using traditional medicine. The treatments are based upon neuromodulation technology. 

Neuronetics became "first and only Food and Drug Administration (FDA) approval for the clinical treatment of a specific form of medication-refractory depression using a TMS Therapy device (FDA approval K061053)."^[5]

They manufacture a transcranial magnetic stimulation device, NeuroStar.^[6] The NeuroStar TMS therapy is delivered via a precisely positioned magnetic coil against the patient's head.^{[7] [8]}

External links

• NeuroStar.com: Neuronetics website

Notes and References

1. Neuronetics Announces the Appointment of Keith J. Sullivan as President and Chief Executive Officer. . Neuronetics . July 15, 2020.
2. Web site: Neuronetics names new CEO. . Seeking Alpha . July 15, 2020.
3. Web site: NeuroStar Executive Team . Neuronetics.
4. Web site: Neuronetics, Inc. (stim) IPO . NASDAQ.com . en-us.
5. The NeuroStar TMS Device: Conducting the FDA Approved Protocol for Treatment of Depression . July 12, 2010. 3159591 . Horvath . J. C. . Mathews . J. . Demitrack . M. A. . Pascual-Leone . A. . Journal of Visualized Experiments . 45 . 2345 . 10.3791/2345 . 21189465 .
6. Web site: Hello Health: How transcranial magnetic stimulation treats major depressive disorder. November 11, 2020.
7. Web site: MercyOne TMS Therapy Des Moines, Iowa. . May 25, 2021.
8. Web site: Neuronetics' NeuroStar TMS device .